Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Perspective Therapeutics is most often covered alongside Assertio Holdings, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 5.1 for the same window.
Last mentioned: Mar 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Perspective Therapeutics is most often covered alongside Assertio Holdings, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 5.1 for the same window. At 5, the average consequence score sits below the same-window beat average of 6.1. We currently track 1 Healthcare story that mention Perspective Therapeutics, all published on March 13, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Perspective Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Perspective Therapeutics and Assertio Holdings are set to report Q4 2025 results, highlighting a divergence between the high-growth radiopharmaceutical sector and the specialty pharma market. Investors are focused on Perspective's clinical pipeline progress and Assertio's efforts to stabilize its commercial portfolio.
Source: Seeking Alpha · Seeking Alpha
Perspective Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
